Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Inclusion Criteria

• •Patients with hematologic malignancy, lymphoma or other HIV-associated malignancy are eligible provided these criteria are met:
• •* The malignancy is in complete remission or very good partial remission, defined as a significant reduction of disease with therapy and no evidence for continued tumor growth in the case of lymphoma or solid tumors
• •* Highly active antiretroviral therapy (HAART) is initiated within one month of hematopoietic cell transplant
• •* Viral load has decreased by \>= 1.5 logs or viral load \< 5000 copies/ml plasma on HAART therapy
• •* CD4 count is allowed to be \> 100 cells/ul
• •HIV infected patients without malignancy who have failed HAART are eligible provided that these criteria are met:
• •* They have been treated with more than one regimen of HAART for a total of at least 6 months duration
• •* The viral load is \< 50 copies/ml plasma
• •* The CD4 count \< 100 cells/ul
• •DONOR: Human leukocyte antigen (HLA) genotypically/phenotypically identical donor; if more than one HLA-identical sibling is available, priority will be given to donors matched for cytomegalovirus (CMV) status, ABO titer, and sex
• •* Peripheral blood stem cells will be collected from donors greater than 12 years of age
• •* Bone marrow will be collected from donors less than 12 years of age
• •DONOR: HLA phenotypically identical unrelated donor; match grades allowed:
• •* Match grade 1: Matched at allele level for HLA-A, B, C, DRB1, and DQB1
• •* Match grade 2.1: Single allele disparity for HLA-A, B, C, DRB1, and DQB1